The utility of a genetic progression risk test for Barrett’s esophagus. Gong, D., et al. Medicine (Baltimore) 101(37): e30503 (2022). Peer-Reviewed Publication.
Validation of a DNA Methylation-Based Diagnostic Assay for Risk Stratification of Patients with Barrett’s Esophagus. Bastakoti, I., et al. Gastroenterology 162: S-714 (2022). Presentation.
Analytical Validation of a DNA Methylation-Based Diagnostic Assay for Risk Stratification of Patients with Barrett’s Esophagus. Laun, S., et al. Gastroenterology 162: S-722 (2022). Presentation.
Impact of a DNA Methylation-Based Assay on Gastroenterologists’ Recommendations for Ablation and Surveillance Time for Risk-Stratified BE Patients: A Randomized Clinical Utility Study. Lu, D., et al., Gastroenterology 162: S-723 (2022). Presentation.
Comparison of Traditional Histology and Histology With Molecular Diagnostic Testing for Risk Stratification of Barrett’s Esophagus: A Multi-Center Study. Stover, J., et al. Gastroenterology 148: S-218. (2015). Poster Presentation.
Clinical Impact of a Genetic Test in the Treatment and Surveillance of Barrett’s Esophagus: A National Community-Based Study of Gastroenterologists. Stover, J., et al. American Journal of Gastroenterology 109: S31 (2014). Poster Presentation.
A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus.” Jin, Z., et al. Cancer Res 69(10): 4112-4115 (2009). Peer-Reviewed Publication.
Three-tiered risk stratification model to predict progression in Barrett’s esophagus using epigenetic and clinical features. Sato, F., et al. PLoS One 3(4): e1890 (2008). Peer-Reviewed Publication.